179 related articles for article (PubMed ID: 29507304)
41. Detecting papillary neovascularization in proliferative diabetic retinopathy using optical coherence tomography angiography.
Savastano MC; Federici M; Falsini B; Caporossi A; Minnella AM
Acta Ophthalmol; 2018 May; 96(3):321-323. PubMed ID: 27495781
[No Abstract] [Full Text] [Related]
42. Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy.
Ren X; Bu S; Zhang X; Jiang Y; Tan L; Zhang H; Li X
Eye (Lond); 2019 Jul; 33(7):1177-1183. PubMed ID: 30872770
[TBL] [Abstract][Full Text] [Related]
43. Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization.
Stergiou PK; Symeonidis C; Dimitrakos SA
Acta Ophthalmol; 2011 May; 89(3):218-21. PubMed ID: 19860769
[TBL] [Abstract][Full Text] [Related]
44. Spontaneous regression of neovascularization at the disc in diabetic retinopathy.
Han JR; Ju WK; Park IW
Korean J Ophthalmol; 2004 Jun; 18(1):41-6. PubMed ID: 15255236
[TBL] [Abstract][Full Text] [Related]
45. The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease.
Zhang L; Ke Y; Wang W; Shi X; Hei K; Li X
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1339-1346. PubMed ID: 29549425
[TBL] [Abstract][Full Text] [Related]
46. Clinical efficacy and acceptability of panretinal photocoagulation combined with conbercept for patients with proliferative diabetic retinopathy: A protocol for systematic review and meta-analysis.
Wang L; Chen Z; Wang X
Medicine (Baltimore); 2021 Apr; 100(17):e25611. PubMed ID: 33907112
[TBL] [Abstract][Full Text] [Related]
47. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S
Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456
[TBL] [Abstract][Full Text] [Related]
48. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
[TBL] [Abstract][Full Text] [Related]
49. Fourier-domain optical coherence tomography evaluation of retinal and optic nerve head neovascularisation in proliferative diabetic retinopathy.
Muqit MM; Stanga PE
Br J Ophthalmol; 2014 Jan; 98(1):65-72. PubMed ID: 24158844
[TBL] [Abstract][Full Text] [Related]
50. One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema.
Li F; Zhang L; Wang Y; Xu W; Jiao W; Ma A; Zhao B
Curr Eye Res; 2018 Feb; 43(2):218-223. PubMed ID: 29265939
[TBL] [Abstract][Full Text] [Related]
51. Intravitreal conbercept improves outcome in patients undergoing vitrectomy for proliferative diabetic retinopathy: A systematic review and meta-analysis.
Pranata R; Vania A
J Evid Based Med; 2020 May; 13(2):116-124. PubMed ID: 32167242
[TBL] [Abstract][Full Text] [Related]
52. Effect of intravitreal conbercept treatment on the expression of Long Noncoding RNAs and mRNAs in Proliferative Diabetic Retinopathy Patients.
Wang J; Gao X; Liu J; Wang J; Zhang Y; Zhang T; Zhang H
Acta Ophthalmol; 2019 Sep; 97(6):e902-e912. PubMed ID: 30900812
[TBL] [Abstract][Full Text] [Related]
53. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Ma Y; Zhang Y; Zhao T; Jiang YR
Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
[TBL] [Abstract][Full Text] [Related]
54. Effect of prophylactic anti-VEGF injections on the prevention of recurrent vitreous hemorrhage in PDR patients after PRP.
Lim JW; Lee SJ; Sung JY; Kim JS; Nam KY
Sci Rep; 2022 Aug; 12(1):14484. PubMed ID: 36008505
[TBL] [Abstract][Full Text] [Related]
55. RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
Manabe A; Shimada H; Hattori T; Nakashizuka H; Yuzawa M
Retina; 2015 Sep; 35(9):1800-7. PubMed ID: 25932549
[TBL] [Abstract][Full Text] [Related]
56. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
Christenbury JG; Phasukkijwatana N; Gilani F; Freund KB; Sadda S; Sarraf D
Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
[TBL] [Abstract][Full Text] [Related]
57. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY
Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of intravitreal injection of conbercept on non-proliferative diabetic retinopathy: a retrospective study.
Wang J; Jiang PF; Liu M; Kou MR; Lei JY; Yu XT; Zhao Y; Wang H; Zhang LN
J Int Med Res; 2020 Apr; 48(4):300060519893176. PubMed ID: 32241206
[TBL] [Abstract][Full Text] [Related]
59. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.
Mason JO; Nixon PA; White MF
Am J Ophthalmol; 2006 Oct; 142(4):685-8. PubMed ID: 17011869
[TBL] [Abstract][Full Text] [Related]
60. Different determinants of neovascularization on the optic disc and on the retina in patients with severe nonproliferative diabetic retinopathy.
Valsania P; Warram JH; Rand LI; Krolewski AS
Arch Ophthalmol; 1993 Feb; 111(2):202-6. PubMed ID: 7679270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
